Medicine and Dentistry
Patient
100%
Heart Failure
40%
Inpatient
38%
Pulmonary Hypertension
23%
Combination Therapy
19%
Diagnosis
18%
Placebo
16%
Follow up
16%
Implantable Automatic Defibrillator
16%
Therapeutic Procedure
15%
Lead
15%
Complication
12%
Atrial Fibrillation
12%
Age
11%
Paracoccidioidomycosis
11%
Empagliflozin
11%
Mycosis
11%
Clusterin
11%
Natriuretic Factor
11%
Hyperkalemia
11%
Tuberculosis
11%
Percutaneous Aortic Valve Replacement
11%
Acute Kidney Injury
11%
Carbon Dioxide
11%
Cardiac Fibrosis
11%
Arteriosclerosis Obliterans
11%
Ertugliflozin
11%
Brain Natriuretic Peptide
10%
Subcutaneous Implantable Cardioverter Defibrillator
10%
Mortality
9%
Amino Terminal Sequence
9%
Hormone Precursor
9%
Systematic Review
9%
Meta-Analysis
9%
Potassium
8%
All Cause Mortality
8%
Shock (Circulatory)
8%
Diseases
8%
Cardiovascular System
8%
Systemic Mycosis
8%
Amaurosis
7%
Case Report
7%
Female
7%
Eisenmenger's Syndrome
7%
Hospital
7%
Aortic Valve Replacement
7%
Marker
6%
Consensus
6%
Patiromer
6%
Sodium Zirconium Cyclosilicate
6%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
23%
Placebo
17%
Atrial Fibrillation
12%
Empagliflozin
11%
Pulmonary Hypertension
11%
Clusterin
11%
Carbon Dioxide
11%
Ertugliflozin
11%
Acute Heart Infarction
11%
Acute Kidney Failure
11%
Diabetes Mellitus
9%
Blindness
8%
Antioxidant
8%
Iodinated Contrast Medium
6%
Low Density Lipoprotein Cholesterol
6%
Adverse Event
5%
Mortality
5%
Observational Study
5%
Randomized Controlled Trial
5%
Biological Marker
5%
Nursing and Health Professions
Defibrillator
11%
Heart Failure
11%
Acute Kidney Failure
11%
Clusterin
11%
Contrast
11%
Pulmonary Hypertension
11%
Carbon Dioxide
11%
Inpatient
11%
Iodinated Contrast Medium
6%
Low Density Lipoprotein Cholesterol
6%
Patient
5%
Low Density Lipoprotein Cholesterol Level
5%
